Theravance Biopharma Announces Participation in Upcoming Investor Conferences
DUBLIN – Theravance Biopharma, Inc. (NASDAQ: TBPH) today made a noteworthy announcement regarding its participation in several key investor conferences scheduled for December. These events are crucial for the company as they aim to showcase their progress and strategies to potential investors.
Upcoming Investor Events
Among the prominent events where Theravance will be featured is the 8th Annual Evercore Healthcare Conference. This conference will take place in Coral Gables, Florida, and will include a unique fireside chat format.
Evercore Healthcare Conference Details
The Evercore conference is set for Thursday, December 4, and Theravance's management team will present from 8:20 to 8:40 AM ET. Investors attending this conference will have an excellent opportunity to glean insights into the company’s future directions.
Oppenheimer Movers in Rare Disease Summit
Another significant event for Theravance is the Oppenheimer Movers in Rare Disease Summit, occurring on Thursday, December 11. This summit, held in New York, will feature Theravance's participation in panel discussions highlighting breakthroughs in rare disease treatments.
These conferences underscore Theravance's commitment to connecting with investors and sharing critical updates. The company has arranged for one-on-one meetings during both events, allowing interested stakeholders to engage directly with the management teams.
Accessing Live and Archived Presentations
Theravance recognizes the importance of these discussions and will provide a live webcast of the Evercore presentation. Interested individuals can find the webcast on the "Events and Presentation" page within the Investors section on Theravance's website. Following the live event, a replay of the presentation will be accessible for 30 days, giving investors ample time to review the information shared.
About Theravance Biopharma
Theravance Biopharma is dedicated to providing Medicines that Make a Difference in patients' lives. This commitment has propelled the company into the limelight, especially with its FDA-approved product, YUPELRI (revefenacin), used in treating chronic obstructive pulmonary disease (COPD). Moreover, the firm's late-stage investigational drug, Ampreloxetine, which targets neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), exemplifies its innovative spirit towards developing groundbreaking therapies.
Contact and Additional Information
For those seeking further details about the company and its upcoming presentations, Theravance encourages visiting their official website. The company's commitment extends to delivering continuous updates, ensuring that stakeholders are informed.
Frequently Asked Questions
What is the purpose of Theravance participating in these conferences?
The company's participation seeks to engage with investors and share insights about its developments and future strategies.
Where will Theravance's presentations be held?
Presentations will take place during the Evercore Healthcare Conference in Coral Gables, Florida, and the Oppenheimer Movers in Rare Disease Summit in New York.
How can investors access the presentations?
Investors can access the presentations via the live webcast on Theravance's official website, which will also host replay access for 30 days.
What are the key products of Theravance Biopharma?
Theravance focuses on its FDA-approved product YUPELRI for COPD and Ampreloxetine for treating neurogenic conditions, aiming to innovate patient care.
How does Theravance aim to improve shareholder value?
Theravance is committed to driving shareholder value through sustainable growth and the development of impactful medical therapies.
